Article

BPH drug's label changes because of possible floppy iris syndrome

The FDA approved changes to the product label of Boehringer Ingelheim's tamsulosin HCl (Flomax), a treatment for benign prostatic hyperplasia. Revisions were made to the Precautions and Adverse Reactions sections of the prescribing information, due to a surgical condition that has sometimes been observed during phacoemulsification in patients treated with alpha-1 blockers, such as tamsulosin HCl. In most reports, the condition, intraoperative floppy iris syndrome (IFIS), occurred in patients taking the alpha-1 blocker. In some cases, the alpha-1 blocker had been stopped prior to surgery.

During questioning for medical history, ophthalmologists should specifically ask male patients being considered for cataract surgery if they have taken tamsulosin HCl or other alpha-1 blockers. If so, the ophthalmologist should be prepared for possible modifications to the surgical technique if IFIS is observed during the procedure.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.